Page 42 - TD-1-2

Tumor Discovery Fact & challenges of immunotherapy in TNBC

52. D’Angelo SP, Lebbe C, Mortier L, et al., 2021, First-line triple-negative breast cancer. Cancer Immunol Immunother.,
avelumab in a cohort of 116 patients with metastatic 70(3): 607–617.
Merkel cell carcinoma (JAVELIN Merkel 200): Primary 64. Reck M, Mok TS, Mansfield A, et al., 2022, Brief report:
and biomarker analyses of a phase II study. J Immunother Exploratory analysis of maintenance therapy in patients with
Cancer, 9(7): e002646. extensive-stage SCLC treated first line with atezolizumab
53. Monk BJ, Colombo N, Oza AM, et al., 2021, Chemotherapy plus carboplatin and etoposide. J Thorac Oncol., 17(9):
with or without avelumab followed by avelumab 1122–1129.
maintenance versus chemotherapy alone in patients with 65. Chen L, Zhou L, Wang C, et al., 2019, Tumor-targeted drug
previously untreated epithelial ovarian cancer (JAVELIN and CpG delivery system for phototherapy and docetaxel-
Ovarian 100): An open-label, randomised, phase 3 trial. enhanced immunotherapy with polarization toward
Lancet Oncol., 22(9): 1275–1289. M1-type macrophages on triple negative breast cancers. Adv
54. Chao J, Fuchs CS, Shitara K, et al., 2021, Assessment of Mater., 31(52): e1904997.
pembrolizumab therapy for the treatment of microsatellite 66. Socinski MA, Nishio M, Jotte RM, et al., 2021, IMpower150
instability-high gastric or gastroesophageal junction cancer final overall survival analyses for atezolizumab plus
among patients in the KEYNOTE-059, KEYNOTE-061, and bevacizumab and chemotherapy in first-line metastatic
KEYNOTE-062 clinical trials. JAMA Oncol., 7(6): 895–902. nonsquamous NSCLC. J Thorac Oncol., 16(11): 1909–1924.
55. Keeping S, Wu E, Chan K, et al., 2018, Pembrolizumab versus 67. Zhang H, Xie W, Zhang Y, et al., 2022, Oncolytic
the standard of care for relapsed and refractory classical adenoviruses synergistically enhance anti-PD-L1 and
Hodgkin’s lymphoma progressing after brentuximab anti-CTLA-4 immunotherapy by modulating the tumour
vedotin: An indirect treatment comparison. Expert Rev microenvironment in a 4T1 orthotopic mouse model.
Hematol., 11(6): 503–511. Cancer Gene Ther., 29(5): 456–465.
56. Kwon M, An M, Klempner SJ, et al., 2021, Determinants 68. Emens LA, Cruz C, Eder JP, et al., 2019, Long-term clinical
of response and intrinsic resistance to PD-1 blockade in outcomes and biomarker analyses of atezolizumab therapy
microsatellite instability-high gastric cancer. Cancer Discov., for patients with metastatic triple-negative breast cancer:
11(9): 2168–2185. A phase 1 study. JAMA Oncol., 5(1): 74–82.
57. Qiu P, Guo Q, Yao Q, et al., 2021, Characterization of 69. Schmid P, Adams S, Rugo HS, et al., 2018, Atezolizumab and
exosome-related gene risk model to evaluate the tumor nab-paclitaxel in advanced triple-negative breast cancer.
immune microenvironment and predict prognosis in triple- N Engl J Med., 379(22): 2108–2121.
negative breast cancer. Front Immunol., 12: 736030.
70. Syn NL, Teng MW, Mok TS, et al., 2017, De-novo and
58. Sacco AG, Chen R, Worden FP, et al., 2021, Pembrolizumab acquired resistance to immune checkpoint targeting. Lancet
plus cetuximab in patients with recurrent or metastatic head Oncol., 18(12): e731–e741.
and neck squamous cell carcinoma: An open-label, multi-
arm, non-randomised, multicentre, phase 2 trial. Lancet 71. Jinnai D, 1972, Surgical treatment of stomach cancer:
Oncol., 22(6): 883–892. Extensive excision of the lymph nodes, with special reference
to radical surgery of stomach cancer. Gan No Rinsho, Suppl:
59. Schmid P, Cortes J, Dent R, et al., 2022, Event-free survival 245–251. Japanese.
with pembrolizumab in early triple-negative breast cancer.
N Engl J Med., 386(6): 556–567. 72. Meighen EA, Nicoli MZ, Hastings JW, 1971, Functional
differences of the nonidentical subunits of bacterial
60. Sun JM, Shen L, Shah MA, et al., 2021, Pembrolizumab luciferase. Properties of hybrids of native and chemically
plus chemotherapy versus chemotherapy alone for modified bacterial luciferase. Biochemistry, 10(22):
first-line treatment of advanced oesophageal cancer 4069–4073.
(KEYNOTE-590): A randomised, placebo-controlled, phase
3 study. Lancet, 398(10302): 759–771. 73. Vonderheide RH, LoRusso PM, Khalil M, et al., 2010,
Tremelimumab in combination with exemestane in patients
61. Zhang J, Zhang G, Zhang W, et al., 2022, Loss of RBMS1 with advanced breast cancer and treatment-associated
promotes anti-tumor immunity through enabling PD-L1 modulation of inducible costimulator expression on patient
checkpoint blockade in triple-negative breast cancer. Cell T cells. Clin Cancer Res., 16(13): 3485–3494.
Death Differ., 29: 2247–2261.
74. Miles D, Gligorov J, Andre F, et al., 2021, Primary results
62. Winer EP, Lipatov O, Im SA, et al., 2021, Pembrolizumab from IMpassion131, a double-blind, placebo-controlled,
versus investigator-choice chemotherapy for metastatic randomised phase III trial of first-line paclitaxel with or
triple-negative breast cancer (KEYNOTE-119): without atezolizumab for unresectable locally advanced/
A randomised, open-label, phase 3 trial. Lancet Oncol., metastatic triple-negative breast cancer. Ann Oncol., 32(8):
22(4): 499–511. 994–1004.
63. Kwapisz D, 2021, Pembrolizumab and atezolizumab in 75. Oki E, Makiyama A, Miyamoto Y, et al., 2021, Trifluridine/

Volume 1 Issue 2 (2022) 10 https://doi.org/10.36922/td.v1i2.196